Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388320 | 0.87 | PKM (0.77) | PKMNPSR1TDP1STAT3HTT | |
| SCHEMBL2592861 | 0.87 | PKM (1.00) | PKMALDH1A1KMT2ANPSR1TDP1 | |
| SCHEMBL25139750 | 0.87 | PKM (0.58) | PKMALDH1A1MEN1KMT2ASTAT3 | |
| SCHEMBL31525863 | 0.85 | PKM (0.69) | PKMALDH1A1NPSR1TDP1STAT3 | |
| SCHEMBL13543708 | 0.85 | PKM (0.74) | PKMALDH1A1NPSR1TDP1STAT3 | |
| SCHEMBL21962198 | 0.85 | PKM (0.74) | PKMALDH1A1KMT2ANPSR1STAT3 | |
| SCHEMBL11264181 | 0.85 | SMN1; SMN2 (0.59) | PKMALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL20057665 | 0.84 | PKM (0.56) | PKMALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL31172621 | 0.83 | PKM (0.54) | PKMALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL28042445 | 0.83 | PKM (0.54) | PKMALDH1A1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-0964849-B1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1270554-A1 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| US-4217305-A | HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | PKM 2293/4885ALDH1A1 2242/4885MEN1 4459/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | PKM 2293/4885ALDH1A1 2242/4885MEN1 4459/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | PKM 3918/4885ALDH1A1 1068/4885MEN1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.